Ojjaara® (momelotinib)
for Myelofibrosis
Ojjaara (momelotinib) is used to treat adults with certain types of myelofibrosis (MF) associated with anemia. It works by targeting and blocking specific enzymes, JAK1, JAK2, and a mutated form of JAK2, which regulate blood cell production and inflammation. Mutations in these enzymes are linked to blood cancers like leukemias, lymphomas, and myeloproliferative diseases. Ojjaara helps manage symptoms and disease progression in MF.
